| scholarly article | Q13442814 |
| P50 | author | Ian F. Parney | Q47328401 |
| John C Bell | Q88475862 | ||
| P2093 | author name string | Tommy Alain | |
| Peter A Forsyth | |||
| Donna L Senger | |||
| XueQing Lun | |||
| Randal N Johnston | |||
| Kelley Parato | |||
| Mark Hamilton | |||
| Brian Lichty | |||
| Anthony Power | |||
| Andra Oprea | |||
| Dave Stojdl | |||
| P2860 | cites work | Intergeneric poliovirus recombinants for the treatment of malignant glioma | Q24682902 |
| Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction | Q25938986 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival | Q30954768 | ||
| Epidemiology and etiology of gliomas | Q30981828 | ||
| Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential | Q33780536 | ||
| Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant | Q33804845 | ||
| Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma | Q33905047 | ||
| Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial | Q33905053 | ||
| Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus | Q33908950 | ||
| The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study | Q34124333 | ||
| VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents | Q34273164 | ||
| Replication-selective virotherapy for cancer: Biological principles, risk management and future directions | Q34297058 | ||
| Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas | Q34297434 | ||
| Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice | Q34371450 | ||
| Reovirus therapy of tumors with activated Ras pathway | Q34479740 | ||
| Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes | Q35043106 | ||
| Adenoviral vectors: systemic delivery and tumor targeting | Q35043111 | ||
| Current and future strategies for the treatment of malignant brain tumors. | Q35095713 | ||
| Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment | Q35107972 | ||
| Oncolytic adenoviruses for malignant glioma therapy | Q35109554 | ||
| Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas | Q35216380 | ||
| Vesicular stomatitis virus as an oncolytic vector | Q36020593 | ||
| Recent progress in the battle between oncolytic viruses and tumours | Q36315580 | ||
| Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody | Q37051843 | ||
| Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo | Q39756181 | ||
| Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. | Q40453751 | ||
| Treatment of multi-focal colorectal carcinoma metastatic to the liver of immune-competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus. | Q40459933 | ||
| Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme | Q40495113 | ||
| Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer | Q40515050 | ||
| Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus | Q40532800 | ||
| Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis | Q40906922 | ||
| 1995 Whitaker Lecture: delivery of molecules, particles, and cells to solid tumors | Q41139696 | ||
| Quantitative estimates of vascularity in solid tumors by non-invasive near-infrared spectroscopy | Q42259746 | ||
| Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis | Q42447740 | ||
| A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. | Q42639115 | ||
| Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy | Q42829776 | ||
| Defective translational control facilitates vesicular stomatitis virus oncolysis | Q42831942 | ||
| Efficient gene transfer of VSV-G pseudotyped retroviral vector to human brain tumor | Q43583247 | ||
| Reovirus as an oncolytic agent against experimental human malignant gliomas | Q43646730 | ||
| Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors | Q43918962 | ||
| Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses | Q43941683 | ||
| Tumor-specific intravenous gene delivery using oncolytic adenoviruses | Q44571557 | ||
| Getting oncolytic virus therapies off the ground | Q45722385 | ||
| Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus | Q45745964 | ||
| Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant | Q45854779 | ||
| Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results | Q45863348 | ||
| Quantitation of HSV mass distribution in a rodent brain tumor model. | Q45872410 | ||
| Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect | Q48186495 | ||
| Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. | Q50782320 | ||
| MTH-68/H oncolytic viral treatment in human high-grade gliomas. | Q53347956 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vesicular stomatitis | Q11549084 |
| P304 | page(s) | 1546-1557 | |
| P577 | publication date | 2006-11-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas | |
| P478 | volume | 98 |
| Q42795549 | Activating Peripheral Innate Immunity Enables Safe and Effective Oncolytic Virotherapy in the Brain |
| Q37287118 | Advances in oncolytic virus therapy for glioma |
| Q37115384 | Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth |
| Q59355808 | Chikungunya-vesicular stomatitis chimeric virus targets and eliminates brain tumors |
| Q35210355 | Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti tumor efficacy: a mathematical model |
| Q37256658 | Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma |
| Q40444017 | Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers |
| Q34318157 | Current status of gene therapy for brain tumors. |
| Q39473679 | Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling. |
| Q36549443 | EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA |
| Q34343768 | Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. |
| Q37564490 | Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways |
| Q33691838 | Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy |
| Q39417318 | Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectors |
| Q33620680 | Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models |
| Q39430229 | Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. |
| Q39796367 | Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma |
| Q36740297 | HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy |
| Q42094345 | Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma |
| Q33523284 | Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice |
| Q38886667 | Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors |
| Q37373616 | Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV. |
| Q36751597 | Murine Tumor Models for Oncolytic Rhabdo-Virotherapy |
| Q38253056 | Newcastle disease virus interaction in targeted therapy against proliferation and invasion pathways of glioblastoma multiforme. |
| Q56892727 | Oncolytic Viruses as Therapeutic Tools for Pediatric Brain Tumors |
| Q33750535 | Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors |
| Q35077031 | Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo |
| Q27007519 | Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates |
| Q36769180 | Oncolytic viruses in cancer therapy |
| Q39804428 | Peripheral immunization blocks lethal actions of vesicular stomatitis virus within the brain. |
| Q33579385 | Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer |
| Q40129203 | Proteolytic disassembly is a critical determinant for reovirus oncolysis |
| Q80162686 | Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy |
| Q45324769 | Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update |
| Q34133011 | Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models |
| Q33832168 | Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates |
| Q37602550 | Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma |
| Q39776032 | Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells |
| Q36928622 | Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus |
| Q64244093 | Synergistic Effects of Bortezomib-OV Therapy and Anti-Invasive Strategies in Glioblastoma: A Mathematical Model |
| Q33320604 | Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. |
| Q39590545 | Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus |
| Q34659011 | Targeting cancer-initiating cells with oncolytic viruses |
| Q35234447 | Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. |
| Q34262327 | Targeting pediatric cancer stem cells with oncolytic virotherapy |
| Q43778531 | The histone deacetylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncolysis of human glioma cells |
| Q37033414 | The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. |
| Q34262131 | Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector. |
| Q33667768 | Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production |
| Q36911654 | Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes |
| Q39013686 | Vesiculovirus neutralization by natural IgM and complement |
| Q30495981 | Viral strategies for studying the brain, including a replication-restricted self-amplifying delta-G vesicular stomatis virus that rapidly expresses transgenes in brain and can generate a multicolor golgi-like expression |
Search more.